Besides stimulating GH release, some GH secretagogues also release ACTH and adrenal steroids. Several novel classes of potent GH secretagogues have recently been described, and we have now tested their ability to release corticosterone in conscious normal rats. All analogs that released GH also stimulated corticosterone release to some degree, though the relative effects on GH and corticosterone varied somewhat. The corticosterone responses for some analogs were in the range of those obtained with CRF (2 g, iv), whereas closely related analogs inactive for GH release failed to release corticosterone. Activation of the hypothalamic-pituitary-adrenal axis with GH release by GHRPs could be a highly diabetogenic combination in susceptible individuals. Therefore, a potent GHRP pentapeptide analog (G7039, 100 g/day, sc, bid) was given to young obese male Zucker diabetic fatty rats (ZDF, n ϭ 8/group) for 24 days. Other groups received hGH (500 g/day, sc, bid), recombinant human insulin-like growth factor (rhIGF)-1 (750 g/day, sc, infusion) or excipient, alone or in combination. Both G7039 and hGH increased weight gain, markedly raised serum glucose (G7039, 542 Ϯ 37; hGH, 725 Ϯ 30; excipient, 330 Ϯ 57 mg/dl) and doubled insulin levels but had opposite effects on serum triglycerides (G7039, 1412 Ϯ 44; hGH 501 Ϯ 46; excipient 1058 Ϯ 73 mg/dl) and fat depot weights. In contrast, treatment with IGF-1, alone or in combination with hGH or G7039, improved the diabetic state and stimulated growth. Thus, both G7039 and hGH treatment stimulated growth in ZDF rats, but greatly worsened diabetes, unless IGF-1 was coadministered. Some of the effects of G7039 could be explained by GH release, but the effects on blood lipids and body fat were not seen with hGH and may reflect the additional activation of the hypothalamic-pituitary-adrenal axis by the secretagogue. The magnitude of these adverse effects in the ZDF animals suggest that chronic administration of GHRP analogs with cortisolreleasing activity to obese or diabetes-prone individuals warrants careful evaluation. (Endocrinology 138: 4316 -4323, 1997) T HERE IS much current interest in new classes of compounds that cause the pituitary to release GH (1). Initial studies with the prototype molecule GHRP-6 developed by Bowers and his colleagues (2) suggested that this hexapeptide was specific for GH release. More recent in vivo experiments have shown that PRL, ACTH, and corticosteroids are also elevated in response to GHRPs (3, 4, 5, 6, 7), but the biological significance of stimulation of the hypothalamicpituitary-adrenal (HPA) axis is unclear (8). The mechanism by which GHRP analogs stimulate the HPA axis is unknown but probably reflects a hypothalamic action because no effect on ACTH release from isolated pituitary cells has been observed (9). However, whether the GH-, and ACTH-releasing activities are intrinsic to GHRP-receptor stimulation or can be separated in different analogs has not been investigated. The first aim of this study was to investigate in vivo the corticosterone-releasing activity of novel GHRP analogs of different sizes and classes that have recently been developed and characterized (10, 11).
T HERE IS much current interest in new classes of compounds that cause the pituitary to release GH (1) . Initial studies with the prototype molecule GHRP-6 developed by Bowers and his colleagues (2) suggested that this hexapeptide was specific for GH release. More recent in vivo experiments have shown that PRL, ACTH, and corticosteroids are also elevated in response to GHRPs (3, 4, 5, 6, 7) , but the biological significance of stimulation of the hypothalamicpituitary-adrenal (HPA) axis is unclear (8) . The mechanism by which GHRP analogs stimulate the HPA axis is unknown but probably reflects a hypothalamic action because no effect on ACTH release from isolated pituitary cells has been observed (9) . However, whether the GH-, and ACTH-releasing activities are intrinsic to GHRP-receptor stimulation or can be separated in different analogs has not been investigated. The first aim of this study was to investigate in vivo the corticosterone-releasing activity of novel GHRP analogs of different sizes and classes that have recently been developed and characterized (10, 11) .
Initial results with GH secretagogue administration to normal adults suggest that HPA activation is relatively slight and may be of little clinical significance (3) . However, consistent stimulation of cortisol together with GH release could be a highly diabetogenic combination in the longer term and could have adverse consequences for the therapeutic use of GHRPs for growth promoting activity in children or metabolic stimulation in elderly or obese adults. The second aim of this study was to compare the diabetogenic activity of a potent GHRP analog with that of GH in an appropriate animal model. Zucker (fa/fa) rats (12) are a well known model of obesity in the rat. A substrain, the Zucker Diabetic Fatty (ZDF) is a rodent model of type II diabetes (13) as it rapidly develops obesity and insulin resistance with progressive ␤-cell failure and subsequent frank diabetes (14) . Furthermore, the adrenal axis has been shown to have a significant impact on the severity of diabetes in the ZDF rat, as adrenalectomy significantly ameliorates the severity of their diabetes (15) . We have therefore examined the growthpromoting and diabetogenic effects of a GHRP analog and of GH, given separately or in combination with IGF-1, to ZDF rats.
Materials and Methods
All procedures involving the use of animals were carried out following appropriate National and Institutional guidelines.
Exp 1
Groups of male rats (200 -250 g, NIMR:AS strain) were equipped with chronic indwelling iv catheters under halothane anesthesia and attached to an automated blood sampling system, as previously described (16) . Several days later the conscious animals, in an undisturbed state, were given iv injections of saline, ovine CRH, or GHRP analogs, and blood samples withdrawn for assay of corticosterone.
Exp 2
Obese male ZDF rats (Genetic Models Inc., Indianapolis, IN) at 6 weeks of age were group housed in a room controlled for temperature and lighting and fed the pelleted rat diet specified by the breeders (Purina 5008, 6% fat breeder chow) and tap water ad libitum. The rats were weighed on the day of surgery and randomized into 6 groups of 8. Ten lean rats from the same strain served as controls. Blood samples were taken from a tail vein on days 0, 7, and 14. On day 24, a blood sample was withdrawn after a 4-h fast, a dose of 1.5 U/kg insulin (Iletin, Lilly, Indianapolis) was injected ip with a second blood sample taken 30 min later. The rats were then killed, a terminal blood sample obtained, and organs and the inguinal (sc) and retroperitoneal (visceral) fat pads dissected and weighed.
Hormones
For Exp 1, a selection of GHRP analogs of different structural classes were chosen from the series recently reported by McDowell et al. (10) and described in Table 1 . Ovine CRF (2 g) was given as a positive control (17) . The GHRP analogs were initially dissolved at 1 mg/ml in saline, supplemented with ethanol or DMSO where necessary. Before use, these stock solutions were then diluted in a citrate/saline buffer pH 5.6 containing 1 mg/ml mannitol, to give an iv dose ranging from 2-10 g/100 l, which was equipotent for GH release as previously determined by in vivo bioassay (10), whereas inactive analogs were given at 30 g (Table 1) .
For Exp 2, the potent GH secretagogue G7039 (Table 1) was dissolved in a 20 mm sodium acetate buffer, pH 5.0, containing mannitol (0.5 g/liter), and given by twice daily sc injections, using a dose (50 g/ injection, 100 g/day) shown to cause weight gain in the rat in a previous study (10) . Recombinant human GH (rhGH, Genentech) was given sc twice daily (250 g/injection, 500 g/day). rhIGF-1 (Genentech, 13.8 mg/ml in acetate buffer) was given by sc osmotic minipump infusions (Alza, Palo Alto CA, model 2ML4) delivering 758 g/day for 28 days. All rats were given a single ip injection of ketamine (62.5 mg/kg, Ketaset, Fort Dodge Laboratories, Inc., Fort Dodge, IA) and xylazine (12.5 mg/ kg, Rompun, Miles Inc., Shawnee Mission, KS), and the osmotic pumps were inserted while the rats were anesthetized. Control groups received injections or infusions of excipients alone so that all the animals were treated identically in that they were anesthetized, implanted with pumps, and received twice sc daily injections.
Assays
Serum chemistries, including glucose, cholesterol, and triglycerides were measured by standard automated procedures. Insulin was measured by rat specific RIA (Linco Research Inc., St. Charles, MO). Rat GH was measured using the reagents supplied by the NIDDK. Plasma corticosterone was assayed using an ImmunoChem double antibody corticosterone RIA kit (ICN Biomedicals, Costa Mesa, CA). Rat serum was extracted using acid-ethanol as previously described (18) , then IGF-1 was measured using two assays. Rat IGF-I was measured (19) in a specific rat IGF-1 RIA (DSL-2900, DSL, Webster, TX), that does not measure human IGF-1, and total IGF-1 concentrations were measured using an RIA that detects both rat and human IGF-1 (18) .
Analysis
Data are presented as mean Ϯ se of the mean (sem), and were subjected to ANOVA, or ANOVA for repeated measures where appropriate, followed by paired t test or Duncan's new multiple range test as appropriate. A P Ͻ 0.05 was considered significant.
Results

Exp 1: effects of GHRP analogs on corticosterone release
A range of GHRP analogs were tested in normal rats for their ability to release corticosterone (Fig. 1) . Ovine CRF, used as a positive control, raised corticosterone levels 4-fold. In general, the corticosterone releasing activity paralleled the GH-releasing potency of GHRP analogs with different sizes and structures (Table 1) . For example, the parent hexapeptide GHRP-6 (no. 1), a tripeptide (no. 2), a linear tetrapeptide with a sub optimal N-terminus (no. 3), and a cyclic heptapeptide (no. 4), given at doses equipotent for GH release, all showed The GHRP analogs tested in vivo for their ability to stimulate corticosterone release. The structure, relative potency on GH release in vivo in young anesthetized rats as described previously by McDowell et al. (10) , and the dose given to the rats in Fig. 1 is shown. The compounds with "G" numbers were those described by McDowell et al. (10) and Elias et al. (11) . Upper case L-isomer; Lower case D-isomer; B ϭ 2-napthylalanine; ava ϭ 5-aminovaleric acid; bda ϭ butane diamine; bol ϭ D-2-naphthylalanol; inip ϭ isonipecotic acid; npe ϭ 2-napthylethylamine; wol ϭ D-tryptophanol.
a Potency on GH release in vivo relative to GHRP-6 (ϭ100%).
FIG. 1.
Effects of GHRP analogs on corticosterone release in conscious rats. Animals with indwelling venous catheters were given iv injections of saline, ovine CRF (2 g), or a series of GHRP analogs (see Table 1 for description of the analogs and the doses used), whereas blood samples were withdrawn automatically at 10-min intervals, and assayed for corticosterone before (Ϫ10 min, open bars) and after (ϩ30 min, closed bars) injection. Means Ϯ SEM, n ϭ 9 -17/group; *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. similar corticosterone-releasing activity, whereas similar tetrapeptide (no. 5), and dipeptide (no. 6), analogs that were inactive for GH release, were also without effect on corticosterone ( Fig. 1) . However, other analogs did reveal some differences in their relative activity for GH and corticosterone release. The dipeptide analog (no. 7) and the pentapeptide analog G7039 (no. 8) had smaller effects on corticosterone than GHRP-6, despite being, respectively, equipotent or 5-fold more potent on GH release. Interestingly, the dipeptide analog (no. 9), which is virtually inactive on GH release when given in vivo but has a significant (EC 50 11 nm) potency for GH release in vitro, showed no corticosterone-releasing activity in vivo. G7039 was the analog chosen for chronic administration to ZDF rats as, compared with the other compounds tested, it was a potent GH-releaser relative to its activity on corticosterone release.
Exp 2: effects of G7039, GH, or IGF-1 in ZDF rats
Serum IGF-1. Serum IGF-1 levels were measured in the blood samples taken at sacrifice. In the rat-specific IGF-1 RIA (19) levels in obese (1997 Ϯ 98 ng/ml) and lean rats (2214 Ϯ 71 ng/ml) were similar, and treatment of the obese rats with G7039 (2008 Ϯ 142 ng/ml) or GH (2315 Ϯ 170 ng/ml) did not increase IGF-1 levels. Treatment with human IGF-1 caused the amount of rat IGF-1 to fall in rats treated with IGF-1 alone (1293 Ϯ 73 ng/ml, P Ͻ 0.01 vs. obese control) or IGF-1 ϩ G7039 (1117 Ϯ 72 ng/ml, P Ͻ 0.001 vs. obese control) or IGF-1 plus hGH (1546 Ϯ 113 ng/ml, P Ͻ 0.05), confirming the specificity of the rat IGF-1 assay. Using an assay that measures total serum IGF-1 (both rat and human IGF-1) the levels for control lean (501 Ϯ 14 ng/ml) and obese rats (683 Ϯ 87 ng/ml) were not different, and levels were unchanged after treatment with G7039 (476 Ϯ 16 ng/ml) or hGH (585 Ϯ 33 ng/ml). Treatment with IGF-1 alone increased total serum IGF-1 (1639 Ϯ 72 ng/ml) as did treatment with G7039 plus IGF-1 (1471 Ϯ 154 ng/ml) or hGH plus IGF-1 (1484 Ϯ 66 ng/ml). Therefore, given the specificity of the rat IGF-1 assay and the fact that human IGF-1 assays underquantitate rat IGF-1 (19) , there was agreement between the assays on the effects of the treatments.
Body weight gain
The body weight gains for ZDF rats over the first 7 days of treatment are shown in Fig. 2a , whereas the full time course is illustrated in Fig. 2b . G7039 and IGF-1 induced significant (P Ͻ 0.01) weight gain compared with vehicle treated rats by day 2 of treatment (G7039 18.3 Ϯ 1.0 g, IGF-1 21.5 Ϯ 0.7 g, obese controls (13.8 Ϯ 0.4 g), whereas hGH did not increase weight gain at this time (13.6 Ϯ 2.5 g). The weight gain in response to G7039 ϩ IGF-1 (26.8 Ϯ 0.8 g) was greater (P Ͻ 0.05) than that to the combination of hGH ϩ IGF-1 (23.3 Ϯ 1.2 g). All these differences were maintained out to 7 days (Fig. 2a) with the weight gains in rats treated with G7039 (65.8 Ϯ 1.5 g) or hGH (62.0 Ϯ 1.5 g) were greater (P Ͻ 0.01) than in rats treated with excipient (56.1 Ϯ 0.8 g). Over the course of the experiment, the lean control group gained less weight than the obese groups. By day 24, the weight gains for the groups treated with G7039 (177.3 Ϯ 1.9 g) or hGH (182.0 Ϯ 3.5 g) were greater (P Ͻ 0.05) than for the obese controls (169.0 Ϯ 1.6 g), whereas all groups treated with IGF-1 were markedly heavier (Fig. 2b) . The weight gain response to G7039 ϩ IGF-1 (247.4 Ϯ 7.1 g) was similar to that to hGH ϩ IGF-1 (245.2 Ϯ 4.9 g) but significantly greater (P Ͻ 0.05) than for IGF-1 treatment alone (232 Ϯ 2 g). Thus, in this diabetic model, the effect of treating with hGH or G7039 alone had only a small effect compared with that of IGF-1,
Body weight gain in obese type II ZDF male rats for the first 7 days (A) or the entire 24 days (B) of treatment. The rats treated sc with excipient, IGF-1 (758 g/day), G7039 (bid injection, 100 g/day), hGH (bid injection, 500 g/day), the combination of hGH and IGF-1 or the combination of IGF-1 and G7039. Treatment with IGF-1 produced the largest weight gains for any agent given alone. For the first week of treatment (A), the combinations of G7039 plus IGF-1 and hGH plus IGF-1 produced a maintained growth response that was at least additive compared with each agent given alone. However, over the 24 days (Fig. 2B ) the growth responses to G7039 and hGH waned. Means Ϯ SEM, n ϭ 8/group. which when given alone or combination with hGH or G7039 caused a large weight gain.
Organ weights and fat depots
Organ weights were also differentially affected by these treatments. IGF-1 had the largest effects on absolute organ weights, increasing heart, kidney, spleen, and thymus weight but did not affect liver weight. GH increased the weight of all organs studied except the thymus. The only significant effects of G7039 given alone was to decrease the absolute and relative weights of the spleen. In addition G7039 also decreased the effect of IGF-1 on the thymus (IGF-1 810 Ϯ 20 mg vs. G7039 ϩ IGF-1, 710 Ϯ 50 mg, P Ͻ 0.05). Figure 3 shows the wet weights in grams of the inguinal (Fig. 3a) and retroperitoneal (Fig. 3b) body fat depots when killed after 24 days of hormone treatment. The rapid weight gain of the obese control rats is reflected in their depots, which were several times heavier than the depots of the lean rats. None of the treatments reduced the fat pad weights of the obese rats to those of lean controls. However, hGH alone or in combination with IGF-1 significantly reduced inguinal, but not retroperitoneal fat, whereas IGF-1 treatment increased retroperitoneal, but not inguinal fat. G7039 alone did not affect absolute fat pad weights but increased both depot weights when given in combination with IGF-1 (Fig. 3) . The relative fat depot size (expressed as grams per 100 g of body weight) was also increased for the retroperitoneal depot by G7039 plus IGF-1 (control obese 0.71 Ϯ 02 g/100 g vs. 0.81 Ϯ 0.03 g/100g, P Ͻ 0.05). Thus, for similar total body weight increases, animals treated with hGH ϩ IGF-1 or G7039 ϩ IGF-1 showed differential effects on the amount and distribution of body fat depots. Figure 4 shows the changes with time in fasting blood glucose and insulin levels over the course of treatment with these peptides alone or in combination. There was no difference between lean and obese fasting blood glucose values at day 0 of treatment ( Fig. 4b ). Blood glucose remained well controlled in all the groups at 7 days, but by 14 days, the obese rats were developing diabetes (obese controls 218 Ϯ 27 mg/dl, lean controls 140 Ϯ 3 mg/dl). This hyperglycemia 
Diabetic state
FIG. 4. Basal plasma insulin levels (A)
and glucose levels (B) obtained weekly in lean and obese male ZDF rats over 24 days. The rats treated sc with excipient, IGF-1 (758 g/day), G7039 (bid injection, 100 g/day), hGH (bid inject, 500 g/day), the combination of hGH and IGF-1 or the combination of IGF-1 and G7039. Treatment with IGF-1 restrained insulin secretion and the rise in blood glucose. When given alone, or in combination with IGF-1, G7039 was diabetogenic but had a lesser effect than hGH at doses with similar somatogenic effects (Fig. 2) . Means Ϯ SEM, n ϭ 8/group. was exacerbated at 14 days by treatment with G7039 (386 Ϯ 63 mg/dl), and even more so (P Ͻ 0.05) with hGH (504 Ϯ 38 mg/dl). However, the combination of G7039 and IGF-1 resulted in a blood glucose marginally lower (190 Ϯ 27 mg/ dl) than the obese controls, and comparable with that in the rats receiving the combination of hGH and IGF-1 (233 Ϯ 49 mg/dl).
By day 24 the blood glucose of obese rats had risen to more than twice that of the lean controls (330 Ϯ 57 vs. 147 Ϯ 4 mg/dl), and whereas both GHRP and hGH were clearly diabetogenic, the effects were more pronounced in hGHtreated rats (725 Ϯ 30 mg/dl vs. 542 Ϯ 37 mg/dl in G7039-treated rats (P Ͻ 0.05). A similar rank order was seen in the combination of these treatments with IGF-1 at 24 days (Fig.  4) . G7039 ϩ IGF-1 resulted in a lower blood glucose (301 Ϯ 53 mg/dl) than did hGH ϩ IGF-1 treatment (512 Ϯ 55 mg/ dl). However, the glucose values in the G7039 ϩ IGF-1 treated group were elevated (P Ͻ 0.05) compared with animals receiving IGF-1 alone (177 Ϯ 4 mg/dl), which clearly delayed the progression of diabetes in this model.
Serum insulin levels were also measured in these rats (Fig.  4a) . At day 0, the levels in obese rats were elevated compared with lean controls, indicative of the prediabetic state of these young ZDF rats. Although after 7 days all the obese animals continued to maintain their blood sugars within the normal range; this was at the expense of a marked increase in fasting plasma insulin except in the groups receiving IGF-1 either alone, or in combination with G7039. Note again that IGF-1 alone significantly reduced serum insulin levels (obese control, 21 Ϯ 2 ng/ml; IGF-1 treated, 8 Ϯ 1 ng/ml) (Fig. 4a) . Both G7039 and hGH elevated serum insulin (39 Ϯ 6 and 48 Ϯ 6 ng/ml, respectively). However, plasma insulin was significantly lower in the rats treated with G7039 ϩ IGF-1 compared with those treated with hGH ϩ IGF-1 (10 Ϯ 2 ng/ml vs. 25 Ϯ 3 ng/ml, P Ͻ 0.05). Thus, G7039, like hGH is clearly diabetogenic in this model, and this effect can be reduced somewhat by concomitant IGF-1 treatment.
Insulin sensitivity
The blood glucose responses to an insulin challenge were assessed at day 24 of treatment ( Fig. 5) . Thirty minutes after the insulin challenge, blood glucose values were higher in the obese vs. lean animals (277 Ϯ 42 mg/dl vs. 84 Ϯ 8 mg/dl), and in G7039 treated animals were reduced to levels (323 Ϯ 67 mg/dl) not significantly different from those of the obese controls. In hGH-treated rats, blood glucose remained significantly elevated (533 Ϯ 55 mg/dl, P Ͻ 0.05) compared with obese controls or G7039 treated rats (Fig. 5) . Similarly, the blood glucose levels were significantly (P Ͻ 0.05) lower in G7039 ϩ IGF-1 treated rats (238 Ϯ 47 mg/dl) than in hGH ϩ IGF-1 treated rats (388 Ϯ 48 mg/dl). Figure 6 illustrates the serum cholesterol and triglyceride levels in the rats. The most striking finding was the immediate and sustained increase in these metabolites in the animals given G7039 alone or in combination with IGF-1. Cholesterol concentrations were not different at baseline but were raised by G7039 after 7 days (control 100 Ϯ 3 mg/dl vs.
Cholesterol and triglycerides
122 Ϯ 5 mg/dl, P Ͻ 0.05), after 14 days (control 104 Ϯ 2 mg/dl vs. 122 Ϯ 4 mg/dl, P Ͻ 0.05) and 24 days (control 126 Ϯ 3 mg/dl vs. 138 Ϯ 3 mg/dl, P Ͻ 0.05). The combination of G7039 and IGF-1 gave the highest cholesterol (day 24, IGF-1, 132 Ϯ 3 mg/dl vs. IGF-1 plus G7039, 163 Ϯ 8 mg/dl, P Ͻ 0.05). Cholesterol concentrations were not affected by treatment with hGH. Triglyceride concentrations were increased by G7039 after 7 days (control, 281 Ϯ 30 mg/dl vs. 488 Ϯ 60 mg/dl, P Ͻ 0.05), after 14 days (control, 673 Ϯ 53 mg/dl vs. 1218 Ϯ 76 mg/dl, P Ͻ 0.05) and remained elevated at day 24 (control, 1058 Ϯ 73 vs. 1412 Ϯ 44 ng/ml, P Ͻ 0.05). In contrast, the triglyceride concentrations on day 24 were reduced in the rats treated with hGH (501 Ϯ 46 mg/dl, P Ͻ 0.05 vs. control) or hGH plus IGF-1 (634 Ϯ 52 mg/dl, P Ͻ 0.05 vs. control). Treatment with IGF-1 alone restrained the rise in triglycerides (day 0; control, 209 Ϯ 35 mg/dl, IGF-1, 236 Ϯ 20 mg/dl, NS: day 24; control, 1058 Ϯ 73 mg/dl, IGF-1, 666 Ϯ 33 mg/dl, P Ͻ 0.05).
Discussion
This study is the first to examine the diabetogenic activity of a GH secretagogue in a specific model of diabetes and to compare it with the effects of GH alone or given in combination with IGF-1. We show, for the first time, the remarkable and rapid diabetogenic activity of GH in the ZDF rat. Within a week, GH injections elevated insulin and more than doubled fasting blood glucose. Treatment with a combination of hGH and IGF-1 is known to counteract the insulin resistance induced by GH alone (20) , and a similar beneficial reduction FIG. 5. Blood glucose concentrations following an iv insulin challenge (insulin tolerance test) in lean control male rats, and obese ZDF rats treated sc with excipient, IGF-1 (758 g/day), G7039 (bid injection, 100 g/day), hGH (bid inject, 500 g/day), the combination of hGH and IGF-1 or the combination of IGF-1 and G7039. Insulin sensitivity was improved by IGF-1 and when given alone, or in combination with IGF-1, G7039 had a lesser effect on insulin sensitivity (diabetogenic effect) than hGH at doses with similar somatogenic effects. Means Ϯ SEM, n ϭ 8/group. (*, P Ͻ 0.05 vs. excipient; #, P Ͻ 0.05 vs. IGF-1).
in the diabetogenic activity of GH was seen when IGF-1 was given with GH in the ZDF rat, showing that the diabetogenic effects of GH cannot be mediated via IGF-1. In fact, administration of IGF-1 alone powerfully delayed the progression of the diabetes in this model. Young ZDF rats were already hyperinsulinemic before treatments began, and it will be interesting to see if an earlier intervention with IGF-1 could inhibit the development of diabetes in this model, (c.f. studies in juvenile diabetics; see Ref. 21 ).
The major novel finding from this study is that the GH secretagogue G7039, given at a dose (100 g/day) and regimen (twice daily sc injections) that stimulated weight gain in normal adult rats, was also highly diabetogenic, raising blood glucose and insulin levels in ZDF rats within 14 days of treatment. This was somewhat surprising because Zucker rats have been reported to be hyporesponsive to GH secretagogues for GH release (22) , and one might expect that direct sc administration of a large dose of GH twice daily would be more effective than the release of endogenous GH by G7039. GHRP-6 has previously been given (in combination with GHRH) to nondiabetic obese Zucker (fa/fa) rats, but significant increases in plasma IGF-1, insulin, or blood glucose levels over obese controls were not reported (22) .
It was interesting to compare the anabolic effects of GH and G7309. Both agents increased even further the rapid weight gain of these obese animals, but this effect was small compared with the response in normal animals treated with frequent injections of this dose of G7039 (10) or of GH (23) over a similar period (4) . It is likely that the reduced growth response in ZDF rats is due to the evident deterioration in their diabetic state caused by GH or G7039, which would render them GH resistant (24) . Adding IGF-1 to either treatment ameliorates the diabetic state and allows a large growth response (25) . Analogous observations have been made in type 1 diabetic rats, whose growth retardation and insensitivity to GH can be overcome by IGF-1 treatment (24) . The large effects of IGF-1 on whole body size were reflected in large increases in the weight of body organs known to be responsive to either GH or IGF-1 (26, 27) . In comparison, G7039 did not increase organ weights; in fact, when given alone it reduced the weight of the spleen and also it reduced the response to IGF-1 of the thymus. Lymphoid tissues are particularly sensitive to stress hormones, raising the possibility that these effects were due to G7039 increasing the release of adrenal steroids. Despite the dramatic increases in body weight, changes in individual fat depots were not marked, although GH treatment either alone or in combination with IGF-1 did reduce inguinal fat (28, 29) whereas G7039 ϩ IGF-1 increased this fat depot. There was evidence for differential effects on fat depots, implying that they may respond differentially to metabolic hormones in this ZDF model. Differential effects on distribution of fat and mobilization have been reported in humans treated with GH (30) or IGF-1 (31) and in Zucker (fa/fa) rats treated with GH and IGF-1 (29) . The Zucker (fa/fa) obese rats have a mutation in the leptin receptor that renders the animals insensitive to leptin (32) . The susceptibility of ZDF rats and leptin-deficient (ob/ob) mice (33) to the diabetogenic effects of GH suggests interactions between leptin and GH, though our data in ZDF rats show that an intact leptin receptor axis is not required for GH to decrease body fat.
By the end of the experiment, serum cholesterol and triglycerides were elevated in obese ZDF animals compared with lean controls. GH treatment alone or in combination with IGF-1 had no effect on serum cholesterol and reduced serum triglycerides compared with untreated ZDF rats. Surprisingly, G7039 treatment, alone or in combination with IGF-1, increased even further these serum lipids. Because the GH releasing activity of G7039 alone cannot explain this difference, an additional property of G7039, not shared by hGH, must also be responsible for this adverse effect on lipids. Again, it is well known (33) that corticosteroids exacerbate the diabetogenic effects of GH, and all GHRPs after acute administration raise cortisol in normal individuals, so we suggest that activation of the HPA axis in combination with a stimulation of GH most simply explains the differential diabetogenic effects of G7039 in this model.
It is well known that the in vivo vs. in vitro potency of active GHRP analogs for GH release varies widely (10), though whether this reflects differences in metabolic stability or relative access to pituitary vs. hypothalamic targets in unclear. GHRPs do not stimulate cortisol release in hypophysectomized animals (34) , suggesting that they do not directly affect the adrenals, nor do they stimulate ACTH release from pituitary cells in vitro (9, 11) . In addition the ACTH response to GHRP is abrogated in pituitary stalk sectioned animals (35) . Rather, just as they activate hypothalamic mechanisms controlling GH release (36) , GHRPs also seem to activate hypothalamic mechanisms controlling ACTH release, either by releasing CRH or AVP or by synergizing with their actions on ACTH release (17) . Because only a single GHRP receptor has been identified to date (37) , it is uncertain whether the in vivo ACTH-releasing and GH-releasing activities of GHRPs can be separated. We therefore tested the corticosteronereleasing activity of a range of novel GHRP analogs of different size and structures, whose in vivo and in vitro potency for GH release in the rat had already been well documented (10) .
Whereas all the potent GH secretagogues tested had some corticosterone-releasing activity, and inactive analogs did not, the relative amounts of corticosterone release varied quite widely. One analog had a high in vitro potency but low in vivo potency for GH release, and this had no effect on corticosterone release, again suggesting that direct pituitary stimulation is unlikely to be involved in ACTH release. We cannot be sure that the differences observed reflect intrinsic potency differences, or the difference between solely hypothalamic activation of ACTH vs. hypothalamic and pituitary activation for GH. It could also reflect differences in access to the separate hypothalamic centers that control ACTH or GH release. Now that the GHRP receptor has been identified, it should be possible to identify the neuronal target that mediates activation of the HPA axis by GHRPs and to establish whether this stimulation can be separated from GH release by further analog development.
Even if the ACTH-and GH-releasing activities are intrinsic to the same receptor activation pathway, the relative magnitude of GH and ACTH release may vary markedly. For example, the combination of GHRPs with GHRH produce a synergistic effect on GH release but not on ACTH release, effectively enhancing the specificity of the response several fold (38) , whereas the negative feedback effects of raised cortisol may be more pronounced on ACTH than on GH responses to GHRPs. Elevations in fasting blood glucose have been reported in elderly subjects dosed with an orally active GHRP for 4 weeks (39), so further work is clearly needed because even a small but consistent rise in cortisol accompanying GH stimulation could provide an undesirable extra diabetogenic drive in susceptible individuals. Finally, if ACTH release is an intrinsic property of GHRP receptor activation, then it is an intriguing possibility that when the endogenous GHRP ligand(s) are identified they may prove to play a role in the endogenous endocrine mechanisms controlling ACTH release as well as GH release, perhaps regulating the very same metabolic interactions between adrenal steroids and GH in normal subjects that they exaggerate in diabetes-prone individuals.
